| BAC |
Report |
Diluted EPS |
BEAT |
pred ~$1.14 vs. cons $1.12 |
MEDIUM |
| BAC |
Report |
Net interest income (GAAP) |
IN-LINE |
pred ~$16.0B vs. cons $16.1B |
MEDIUM |
| BAC |
Report |
Sales & trading revenue |
BEAT |
pred ~$5.9B vs. cons $5.6B |
MEDIUM |
| BAC |
Guide |
FY2026 NII growth guide |
BETTER |
guide ~+7-8% vs. cons ~+7% (FY2026 vs 2025) |
MEDIUM |
| BAC |
Guide |
FY2026 operating leverage target |
UNCHANGED |
guide ~200-300 bps vs. cons ~200 bps (FY2026) |
MEDIUM |
| BAC |
Guide |
Quarterly common dividend (post-CCAR) |
BETTER |
guide ~$0.30 vs. cons/current $0.28 (3Q26) |
MEDIUM |
| BAC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.0% |
— |
MEDIUM |
| BAC |
Return |
5-day cumulative residual |
+0.2% (FADE) |
A clean beat led by volatile trading plus in-line NII and a likely dividend bump should pop the stock ~1% on day 1, but follow-through fades: management has flagged that the 2H26 fixed-rate repricing tailwind is smaller than 2H25, so out-quarter NII estimates get little upward revision even after the beat (YoY NII growth decelerates from ~9%). With shares at record highs (elevated bar / results largely priced in), a persistent Berkshire selldown overhang, and peers reporting the same week, the initial gain largely gives back — mirroring the muted 2Q25 reaction (~+0.7% then faded). |
MEDIUM |